Cargando…
Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire
BACKGROUND: Coronavirus disease 2019 (COVID-19) lockdowns disrupted access to harm reduction supplies and services known to be effective in overdose prevention and contributed to a worsening of the opioid crisis. However, because pharmacies can provide naloxone and sell over-the-counter (OTC) steril...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc. on behalf of the American Pharmacists Association.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574786/ https://www.ncbi.nlm.nih.gov/pubmed/36369076 http://dx.doi.org/10.1016/j.japh.2022.10.012 |
_version_ | 1784811176908029952 |
---|---|
author | Bolivar, Derek Hartung, Daniel Silcox, Joseph Bratberg, Jeffrey Boggis, Jesse Rabin, Megan Green, Traci C. |
author_facet | Bolivar, Derek Hartung, Daniel Silcox, Joseph Bratberg, Jeffrey Boggis, Jesse Rabin, Megan Green, Traci C. |
author_sort | Bolivar, Derek |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) lockdowns disrupted access to harm reduction supplies and services known to be effective in overdose prevention and contributed to a worsening of the opioid crisis. However, because pharmacies can provide naloxone and sell over-the-counter (OTC) sterile syringes, their continued operation throughout the pandemic potentially reinforced a public health role as a distribution hub for safer use supplies. OBJECTIVES: The objective of this analysis was to examine patterns of naloxone and OTC syringe sale volume at 463 community pharmacies in 2 states with high overdose rates during the COVID-19 pandemic. METHODS: We analyzed weekly pharmacy-level dispensing data from January 5, 2020, to December 31, 2020, from one corporate community pharmacy chain in Massachusetts (n = 415 pharmacies) and New Hampshire (n = 48 pharmacies). Descriptive statistics and visualizations over the analytical period were generated as initial explorations of the outcome. Zero-inflated Poisson and negative binomial models were used to analyze distribution data along with county-level COVID-19 case rates and store-level COVID-19 testing location status during the same time. Interactions tested the effect of COVID-19 case rates on naloxone and OTC syringe sales. RESULTS: Pharmacies that reported selling nonprescription syringes and dispensing naloxone during the study period averaged 210.13 OTC syringes sold and 0.53 naloxone prescriptions per week. Pharmacies in communities that experienced greater COVID-19 case burden also exhibited higher naloxone dispensing and OTC syringe sales during this period. The odds of selling OTC syringes increased over time but naloxone dispensing remained constant over the pandemic year. Pharmacies hosting COVID-19 testing tended to have lower OTC syringe sales and naloxone provision than nontesting sites. CONCLUSION: During the COVID-19 pandemic, pharmacies provided harm reduction services and dispensed lifesaving medications by quickly adapting to fulfill community needs without disrupting co-located services for COVID-19 response. |
format | Online Article Text |
id | pubmed-9574786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Published by Elsevier Inc. on behalf of the American Pharmacists Association. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95747862022-10-17 Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire Bolivar, Derek Hartung, Daniel Silcox, Joseph Bratberg, Jeffrey Boggis, Jesse Rabin, Megan Green, Traci C. J Am Pharm Assoc (2003) Brief Report BACKGROUND: Coronavirus disease 2019 (COVID-19) lockdowns disrupted access to harm reduction supplies and services known to be effective in overdose prevention and contributed to a worsening of the opioid crisis. However, because pharmacies can provide naloxone and sell over-the-counter (OTC) sterile syringes, their continued operation throughout the pandemic potentially reinforced a public health role as a distribution hub for safer use supplies. OBJECTIVES: The objective of this analysis was to examine patterns of naloxone and OTC syringe sale volume at 463 community pharmacies in 2 states with high overdose rates during the COVID-19 pandemic. METHODS: We analyzed weekly pharmacy-level dispensing data from January 5, 2020, to December 31, 2020, from one corporate community pharmacy chain in Massachusetts (n = 415 pharmacies) and New Hampshire (n = 48 pharmacies). Descriptive statistics and visualizations over the analytical period were generated as initial explorations of the outcome. Zero-inflated Poisson and negative binomial models were used to analyze distribution data along with county-level COVID-19 case rates and store-level COVID-19 testing location status during the same time. Interactions tested the effect of COVID-19 case rates on naloxone and OTC syringe sales. RESULTS: Pharmacies that reported selling nonprescription syringes and dispensing naloxone during the study period averaged 210.13 OTC syringes sold and 0.53 naloxone prescriptions per week. Pharmacies in communities that experienced greater COVID-19 case burden also exhibited higher naloxone dispensing and OTC syringe sales during this period. The odds of selling OTC syringes increased over time but naloxone dispensing remained constant over the pandemic year. Pharmacies hosting COVID-19 testing tended to have lower OTC syringe sales and naloxone provision than nontesting sites. CONCLUSION: During the COVID-19 pandemic, pharmacies provided harm reduction services and dispensed lifesaving medications by quickly adapting to fulfill community needs without disrupting co-located services for COVID-19 response. Published by Elsevier Inc. on behalf of the American Pharmacists Association. 2023 2022-10-15 /pmc/articles/PMC9574786/ /pubmed/36369076 http://dx.doi.org/10.1016/j.japh.2022.10.012 Text en © 2022 Published by Elsevier Inc. on behalf of the American Pharmacists Association. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Brief Report Bolivar, Derek Hartung, Daniel Silcox, Joseph Bratberg, Jeffrey Boggis, Jesse Rabin, Megan Green, Traci C. Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire |
title | Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire |
title_full | Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire |
title_fullStr | Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire |
title_full_unstemmed | Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire |
title_short | Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire |
title_sort | examining the effects of covid-19 on pharmacy dispensing of naloxone and syringes sales across massachusetts and new hampshire |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574786/ https://www.ncbi.nlm.nih.gov/pubmed/36369076 http://dx.doi.org/10.1016/j.japh.2022.10.012 |
work_keys_str_mv | AT bolivarderek examiningtheeffectsofcovid19onpharmacydispensingofnaloxoneandsyringessalesacrossmassachusettsandnewhampshire AT hartungdaniel examiningtheeffectsofcovid19onpharmacydispensingofnaloxoneandsyringessalesacrossmassachusettsandnewhampshire AT silcoxjoseph examiningtheeffectsofcovid19onpharmacydispensingofnaloxoneandsyringessalesacrossmassachusettsandnewhampshire AT bratbergjeffrey examiningtheeffectsofcovid19onpharmacydispensingofnaloxoneandsyringessalesacrossmassachusettsandnewhampshire AT boggisjesse examiningtheeffectsofcovid19onpharmacydispensingofnaloxoneandsyringessalesacrossmassachusettsandnewhampshire AT rabinmegan examiningtheeffectsofcovid19onpharmacydispensingofnaloxoneandsyringessalesacrossmassachusettsandnewhampshire AT greentracic examiningtheeffectsofcovid19onpharmacydispensingofnaloxoneandsyringessalesacrossmassachusettsandnewhampshire |